Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary EDAP Announces Record Q4 US Focal One Placements
Company preliminarily reports nine Focal One Placements in the U.S. , including seven sales LYON, France, January 5, 2023 -- EDAP TMS SA (NASDAQ: EDAP) (the “Company”), the global leader in robotic energy-based therapies, announced today that the Company experienced robust demand for its Focal One
View HTML
Toggle Summary EDAP Appoints Medical Capital Equipment Finance Veteran Ken Mobeck as Chief Financial Officer of Company’s U.S. Subsidiary
LYON, France, December 6, 2022 -- EDAP TMS SA (NASDAQ: EDAP) (the “Company”), the global leader in robotic energy-based therapies, announced today that the Company has hired medical capital equipment finance industry veteran Ken Mobeck as Chief Financial Officer of EDAP Technomed Inc., the
View HTML
Toggle Summary EDAP Announces Approval to Initiate Randomized Clinical Trial Evaluating Focal One® as a Potential Treatment for Rectal Deep Infiltrating Endometriosis
  Study to begin enrolling patients in Q2 2023   Endometriosis represents significant expansion opportunity for Focal One  LYON, France, November 30, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic therapeutic ultrasound, today announced that the Company has
View HTML
Toggle Summary EDAP to Present at the Piper Sandler 34th Annual Healthcare Conference
LYON, France, November 21, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today that Marc Oczachowski, Chief Executive Officer, is scheduled to deliver a company presentation and host investor 1x1 meetings at the Piper Sandler 34 th
View HTML
Toggle Summary EDAP Reports Third Quarter 2022 Results
Generated Q3 2022 total revenue of approximately EUR 12.2 million (USD 12.3 million), an increase of 29.7 % as compared to EUR 9.4 million (USD 11.1 million) for Q3 2021; nine-month year-to-date revenue increased 30.9% compared to the same period in 2021 Generated HIFU sales of EUR $3.5 million
View HTML
Toggle Summary EDAP TMS SA to Announce Third Quarter 2022 Financial Results on Wednesday, November 16th, 2022
Company to host conference call and webcast on Thursday , November 17 th at 8:30 am EDT LYON, France, November 2 , 20 2 2 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended
View HTML
Toggle Summary EDAP Announces Focal One® HIFU Reimbursement Raised to Urology APC Level 6 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY23
Final rule significantly raises Medicare reimbursement to U.S. hospital s performing a Focal One HIFU prostate ablation procedure LYON, France, November 1, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic therapeutic ultrasound, today announced that the U.S.
View HTML
Toggle Summary EDAP TMS Hosting Urology Expert Panel and Live Focal One® Technology Demonstration
September 29, 2022 @ 8 AM ET Langham Hotel, NYC LYON, France, September 26, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic therapeutic ultrasound, announced today it will host a urology expert panel and live Focal One® technology demonstration on September 29, 2022
View HTML
Toggle Summary EDAP Announces Pricing of Public Offering of American Depositary Shares
LYON, France, September 22, 2022 -- EDAP TMS S.A. (NASDAQ: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced that the price of its public offering of its American Depositary Shares (“ADSs”), which commenced on September 22, 2022, has been set today at $7.50 per
View HTML
Toggle Summary EDAP Announces Proposed Public Offering of American Depositary Shares
LYON, France, September 22, 2022 -- EDAP TMS S.A. (NASDAQ: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today that it has commenced a public offering of its American Depositary Shares, or ADSs, each representing one ordinary share of the Company.
View HTML